ARQTHealthcareMid-Cap
Arcutis Biotherapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Arcutis Biotherapeutics, Inc. (ARQT), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are ARQT insiders buying or selling?
Arcutis Biotherapeutics, Inc. insiders reported 20 open-market buys ($71.6M) and 229 sells ($59.0M) across 249 Form 4 filings — a net buying position of $12.6M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 17, 2026)
Total Form 4 filings
249
SEC EDGAR
Insider filers
24
Insider buys (20)
$71.6M
Insider sells (229)
$59.0M
Insider sentiment
Net buyingNet insider flow of $12.6M in net buying.
Recent ARQT insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 17, 2026 | Howard G. Welgus | Director | Sale | 4.7K | $26.91 | $127.3K |
| Jun 18, 2026 | Sue-Jean Lin | Director | Sale | 4.9K | $24.38 | $120.6K |
| Jun 18, 2026 | Howard G. Welgus | Director | Sale | 4.7K | $24.58 | $116.3K |
| May 13, 2026 | Latha Vairavan | SVP Chief Financial Officer | Sale | 435 | $21.05 | $9.2K |
| May 13, 2026 | Patrick Burnett | Reporting Person's Title: EVP, Chief Medical Officer | Sale | 222 | $21.05 | $4.7K |
| May 6, 2026 | Masaru Matsuda | Reporting Person's title: EVP, Chief Legal Officer | Sale | 8.3K | $23.31 | $192.4K |
| May 6, 2026 | Patrick Burnett | Reporting Person's Title: EVP, Chief Medical Officer | Sale | 684 | $23.61 | $16.1K |
| May 6, 2026 | Latha Vairavan | SVP Chief Financial Officer | Sale | 1.3K | $23.61 | $31.7K |
| May 6, 2026 | Todd Watanabe | Reporting Person's title: President and Chief Executive Officer | Sale | 3.2K | $23.61 | $74.9K |
| May 6, 2026 | Howard G. Welgus | Director | Sale | 7.1K | $22.99 | $164.2K |
| Apr 3, 2026 | Howard G. Welgus | Director | Sale | 10.0K | $23.88 | $238.8K |
| Mar 4, 2026 | Keith R Leonard | Director | Sale | 39.3K | $25.39 | $997.2K |
| Mar 4, 2026 | Howard G. Welgus | Director | Sale | 10.0K | $25.65 | $256.5K |
| Mar 4, 2026 | Larry Todd Edwards | Reporting Person's title: EVP, Chief Commercial Officer | Sale | 3.7K | $25.18 | $92.8K |
| Mar 4, 2026 | Todd Watanabe | Reporting Person's title: President and Chief Executive Officer | Sale | 37.3K | $25.18 | $940.5K |
| Mar 4, 2026 | Masaru Matsuda | Reporting Person's title: EVP, Chief Legal Officer | Sale | 12.1K | $26.03 | $313.9K |
| Mar 4, 2026 | Latha Vairavan | SVP Chief Financial Officer | Sale | 2.9K | $25.18 | $71.8K |
| Mar 4, 2026 | Patrick Burnett | Reporting Person's title: EVP, Chief Medical Officer | Sale | 6.3K | $25.18 | $158.3K |
| Feb 5, 2026 | Masaru Matsuda | Reporting Person's title: SVP General Counsel and Corporate Secretary | Sale | 40.6K | $25.28 | $1.0M |
| Feb 5, 2026 | Patrick Burnett | Reporting Person's Title: Executive Vice President and Chief Medical Officer | Sale | 13.5K | $25.72 | $346.5K |
| Feb 5, 2026 | Todd Watanabe | Reporting Person's title: President and Chief Executive Officer | Sale | 19.8K | $25.50 | $505.7K |
| Feb 5, 2026 | Latha Vairavan | SVP Chief Financial Officer | Sale | 1.3K | $25.50 | $33.7K |
| Feb 5, 2026 | Howard G. Welgus | Director | Sale | 10.0K | $25.05 | $250.5K |
| Feb 5, 2026 | Larry Todd Edwards | Reporting Person's title: EVP Chief Commercial Officer | Sale | 2.1K | $25.50 | $52.3K |
| Jan 7, 2026 | Patrick Burnett | Reporting Person's Title: Executive Vice President and Chief Medical Officer | Sale | 2.5K | $28.98 | $72.2K |
Showing the 25 most recent of 249 Form 4 filings for Arcutis Biotherapeutics, Inc..
Most active ARQT insiders
- Todd Watanabe58 filings
- Howard G. Welgus55 filings
- Patrick Burnett30 filings
- Masaru Matsuda24 filings
- David W Osborne9 filings
Ask anything about ARQT insider activity
Use Trabud's AI agent to query Arcutis Biotherapeutics, Inc.'s Form 4 history in plain English — "Show me ARQT CEO purchases this year" or compare it against any other ticker.
Open the AI agentARQT insider trading FAQ
Are Arcutis Biotherapeutics, Inc. insiders buying or selling?
Across 249 SEC Form 4 filings, Arcutis Biotherapeutics, Inc. (ARQT) insiders reported 20 open-market purchases totaling $71.6M and 229 sales totaling $59.0M. That is a net buying position of $12.6M.
How many insiders trade ARQT stock?
24 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Arcutis Biotherapeutics, Inc.. The most recent filing was accepted on Jul 17, 2026.
Where does Trabud get ARQT insider trading data?
All ARQT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.